Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential XELOX followed by TX in unresectable gastric cancer
NCT01331928Phase 2Unknown
- Sponsor
- Taipei Veterans General Hospital
- Start
- Jan 2011
- Primary completion
- Jan 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin, docetaxel in gastric cancer (GC), sponsored by Taipei Veterans General Hospital. Status: unknown.
02
Drugs
capecitabineoxaliplatindocetaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01331928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01331928.